DrugPatentWatch Database Preview
KEYTRUDA Drug Profile
» See Plans and Pricing
Summary for Tradename: KEYTRUDA
| Patents: | 161 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for KEYTRUDA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KEYTRUDA |
Recent Clinical Trials for KEYTRUDA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Partner Therapeutics (PTx) | Phase 2 |
| Biocompatibles UK Ltd | Phase 2 |
| Eisai Inc. | Phase 2 |
Recent Litigation for KEYTRUDA
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| Genome & Company | 2018-10-02 |
Pharmacology for KEYTRUDA
| Mechanism of Action | Programmed Death Receptor-1-directed Antibody Interactions |
Patent Text Search: US Patents for KEYTRUDA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | MedImmune Limited (Cambridge, GB) | 2034-06-17 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Advenchen Pharmaceuticals, LLC (Moorpark, CA) | 2035-05-04 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | Flexus Biosciences, Inc. (Princeton, NJ) | 2034-11-05 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | Start Trial | BIOTHERA, INC. (Eagan, MN) | 2034-11-06 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for KEYTRUDA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20200057790 | Start Trial |
| China | 102665757 | Start Trial |
| South Korea | 20180133395 | Start Trial |
| Japan | 2020515257 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2017211753 | Start Trial |
| Eurasian Patent Organization | 036335 | Start Trial |
| Taiwan | 201718579 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
